Researchers discovered human antibodies targeting PfEMP1 proteins in severe malaria, potentially leading to vaccines or treatments. These antibodies, found effective against various PfEMP1 types, prevent parasite binding by recognizing conserved amino acids on CIDRα1, offering insights for PfEMP1-based interventions.